Dyne Therapeutics (NASDAQ: DYN) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.78) by 6.41 percent. This is a 30.48 percent increase over losses of $(1.05) per share from the same period last year.